<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NARATRIPTAN</span><br/>(nar-a-trip'tan)<br/><span class="topboxtradename">Amerge<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">adrenergic antagonist (sympatholytic)</span>; <span class="classification">5-ht<sub>1</sub> serotonin agonist</span><br/><b>Prototype: </b>Sumatriptan<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg, 2.5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Binds to the serotonin receptors (5HT<sub>1D</sub> and 5HT<sub>1B</sub>) on intracranial blood vessels, resulting in selective vasoconstriction of dilated vessels in the carotid circulation.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits vasoconstriction of dilated vessels selectively and also the release of proinflammatory neuropeptides. This results
         in the relief of acute migraine headache attacks.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute migraine headaches with or without aura.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe renal impairment (creatinine clearance 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiovascular disease; renal or hepatic insufficiency; pregnancy (category C), lactation. Safety and efficacy in children
         
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Migraine</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 12.5 mg; may repeat in 4 h if necessary (max: 5 mg/24 h); patients with mild or moderate renal or hepatic impairment
               should not exceed 2.5 mg/24 h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give any time after symptoms of migraine appear. If the first tablet was effective but symptoms return, a second tablet may
            be given, but no sooner than 4 h after the first. Do not exceed 5 mg in 24 h.
         </li>
<li>If there is no response to the first tablet, contact physician before administering a second tablet.</li>
<li>Do not give within 24 h of an ergot-containing drug or other 5-HT<sub>1</sub> agonist.
         </li>
<li>Store at 2°25° C (36°77° F); protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, fatigue, malaise, pain, pressure sensation, paresthesias, throat pressure, warm/cold sensations, hot flushes. <span class="typehead">CNS:</span> Somnolence, dizziness, drowsiness, headache, hypesthesia, decreased mental acuity, euphoria, tremor. <span class="typehead">CV:</span> Coronary artery vasospasm, transient myocardial ischemia, <span class="speceff-life">MI</span>, ventricular tachycardia, ventricular fibrillation, chest pain/tightness/heaviness, palpitations. <span class="typehead">GI:</span> Dry mouth, nausea, vomiting, diarrhea. <span class="typehead">Respiratory:</span> Dyspnea. <span class="typehead">Skin:</span> Flushing. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Dihydroergotamine,</b> <b>methysergide,</b> and other <span class="classification">5-ht</span> <sub>1</sub> <span class="classification">agonists</span> may cause prolonged vasospastic reactions; <span class="classification">ssri</span>s have rarely caused weakness, hyperreflexia, and incoordination; <span class="classification">maoi</span>s should not be used with <span class="classification">5-ht</span> <sub>1</sub> agonists. <span class="typehead">Herbal:</span> <b>Gingko, ginseng, echinacea, St. John's wort</b> may increase triptan toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed, 70% bioavailability. <span class="typehead">Peak:</span> 24 h. <span class="typehead">Distribution:</span> 2831% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully cardiovascular status following first dose in patients at risk for CAD (e.g., postmenopausal women, men
            over 40 y, persons with known CAD risk factors) or coronary artery vasospasms.
         </li>
<li>Be aware that ECG is recommended following first administration of naratriptan to someone with known CAD risk factors and
            periodically with long-term use.
         </li>
<li>Report immediately to the physician: chest pain, nausea, or tightness in chest or throat that is severe or does not quickly
            resolve.
         </li>
<li>Obtain periodic cardiovascular evaluation with continued use.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Carefully review patient information leaflet and guidelines for administration.</li>
<li>Contact physician immediately for any of the following: symptoms of angina (e.g., severe and/or persistent pain or tightness
            in chest or throat, severe nausea); hypersensitivity (e.g., wheezing, facial swelling, skin rash, or hives); or abdominal
            pain.
         </li>
<li>Report any other adverse effects (e.g., tingling, flushing, dizziness) at next physician visit.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>